What is Transgene Biotek Ltd (526139) share price return in the past 10 years?

Transgene Biotek Ltd share price has appreciated 6.7% annually (CAGR) over the past ten years.

What is the share price of Transgene Biotek Ltd (526139)?

Company share prices are keep on changing according to the market conditions. The current trading price of Transgene Biotek Ltd (526139) on 04-Jun-2026 16:59:59 at 16:59 is 3.13.

What is the P/E ratio of Transgene Biotek?

The latest standalone P/E ratio of Transgene Biotek as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Transgene Biotek Ltd (526139)?

The latest standalone P/B ratio of Transgene Biotek Ltd (526139) as of 04-Jun-2026 is -2.58.

What is the 52-week high and low of Transgene Biotek Ltd (526139)?

The 52-week high of Transgene Biotek Ltd (526139) is Rs. 5.26 and the 52-week low is Rs. 1.83.

Transgene Biotek Ltd (526139) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Transgene Biotek Ltd (526139)
Brand: Transgene Biotek

Transgene Biotek Ltd (526139)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526139 NSE: Business Support | Small Cap | Transgene Biotek Share Price

Transgene Biotek Ltd (526139)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526139 NSE: Business Support | Small Cap | Transgene Biotek Share Price

Key Metrics

Valuation Multiples

Market Cap

₹24 Cr.

Current Price

₹3.1

52-Week Low / High

₹2 / 5

TTM EPS

₹-0.2

TTM Sales

₹0.2 Cr.

Book Value per Share

₹-1.2

P/E Ratio

0.00

Industry PE

Price to Book (P/B)

-2.58

Higher than its 5-year historical median

Price to Sales (P/S)

112.40

Lower than its 5-year historical median

EV/EBITDA

-103.80

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Underperforms industry median

Return on Capital Employed (ROCE)

-6.11%

Underperforms industry median

Return on Assets (ROA)

-2.03%

Operating Profit Margin

-430.2%

Net Profit Margin

-259.34%

Gross Profit Margin

-223.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

13.04%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

23.64%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹-85 Cr.

Equity

₹75.8 Cr.

Face Value

₹10

All Time Low / High

₹0.10 / 322.50

Transgene Biotek stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Transgene Biotek Ltd a good quality company?

Transgene Biotek Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Transgene Biotek Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Transgene Biotek Ltd vs industry peers?

Transgene Biotek Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Transgene Biotek Ltd?

Promoters hold 23.64% of the Transgene Biotek Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Transgene Biotek Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 6.2% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-11.9%	-17.1%	-9.1%	-21.4%	-34.9%	-49.1%	-73.2%	-57.5%	-7.4%	-6.1%	-
Value Creation Index ⓘ	-1.9	-2.2	-1.7	-2.5	-3.5	-4.5	NA	NA	NA	NA	-
Growth Parameters ⓘ
Sales ⓘ	0.2	0.3	0.1	0.1	0	0.2	0.1	0.1	0.2	0.3	0
Sales YoY Gr.	-	55.6%	-57.1%	-41.7%	-100%	NA	-47.1%	-33.3%	283.3%	13%	-
Adj EPS ⓘ	-2.8	-2.6	-1.1	-1.3	-1.5	-1.4	-1.4	-0.8	-0.1	-0.1	-0.2
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	20.4	5.5	4.6	3.4	2	0.6	-0	-0.8	-0.9	-1	-1.2
Adj Net Profit ⓘ	-21.5	-19.9	-8.5	-10	-11	-10.4	-10.4	-6	-0.7	-0.7	-2
Cash Flow from Ops. ⓘ	0	0	-0.6	-1.7	0.1	0	0.1	0	0	1.2	-
Debt/CF from Ops. ⓘ	818	692.9	-15.8	-5.3	74.1	901.5	122.9	43733	3043.7	12.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.2%	NA	42.4%	13%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-171.5%	-187.1%	NA	NA
Share Price	6.7%	-5.4%	-7.2%	-20.2%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-12.9	-20.3	-22.2	-33	-53.3	-105.6	-465.8	187.6	10	9.4	19.9
Op. Profit Mgn % ⓘ	-623.1	-910.9	-1779.2	-944.2	-24147.1	-307.2	-531.8	-1104.2	-258.1	-430.2	-258.1
Net Profit Mgn % ⓘ	-11864.4	-7071.7	-7161.3	-14076	-306601.7	-6153.4	-11998.4	-10901.5	-279.1	-259.3	-793.8
Debt to Equity ⓘ	0.1	0.4	0.3	0.4	0.7	2.4	-61	-2.1	-2	-1.9	-
Working Cap Days ⓘ	1,34,729	54,937	75,086	1,21,127	24,16,578	51,163	1,00,234	1,58,615	37,423	33,676	846
Cash Conv. Cycle ⓘ	18,103	1,132	155	172	3,537	52	234	411	-134	-564	-9,949

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0.18	0.28	0.12	0.07	0	0.17	0.09	0.06	0.23	0.26
Operating Expenses ⓘ +	1.31	2.84	2.22	0.74	0.87	0.69	0.55	0.66	0.84	1.38
Manufacturing Costs	0.15	0.13	0.07	0.10	0.19	0.02	0.01	0.02	0	0
Material Costs	0	0	0.05	0.03	0.01	0.06	-0.05	0.07	0	0
Employee Cost	0.39	0.27	0.20	0.25	0.29	0.25	0.29	0.30	0.31	0.31
Other Costs ⓘ	0.78	2.44	1.90	0.37	0.38	0.37	0.29	0.27	0.53	1.07
Operating Profit ⓘ	-1.13	-2.56	-2.10	-0.67	-0.86	-0.52	-0.46	-0.61	-0.61	-1.12
Operating Profit Margin (%)	-623.0%	-910.0%	-1,779.3%	-944.0%	-24,147.1%	-307.0%	-531.0%	-1,104.2%	-258.0%	-430.0%
Other Income ⓘ +	0.17	0.66	7.37	2.04	0.18	0.27	0.21	0.18	0.18	0.78
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.07	0.43	1.03	0.26	0.38	0.27	0.23	0.62	0.14	0.24
Depreciation ⓘ	20.50	17.53	9.89	9.89	9.90	9.91	9.92	4.95	0.09	0.09
Profit Before Tax ⓘ	-21.54	-19.86	-5.65	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66	-0.68
Tax ⓘ	0	0	0.79	0	0	0	0	0	0	0
Profit After Tax	-21.54	-19.86	-6.44	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66	-0.68
PAT Margin (%)	-11,864.4%	-7,071.7%	-5,445.3%	-12,334.3%	-3,06,601.7%	-6,153.4%	-11,998.4%	-10,901.5%	-279.0%	-259.0%
Adjusted EPS (₹)	-2.8	-2.6	-0.9	-1.2	-1.5	-1.4	-1.4	-0.8	-0.1	-0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Transgene Biotek - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	154.66	41.29	34.85	26.06	15.10	4.66	-0.20	-6.21	-6.87	-7.55
Share Capital ⓘ	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77
Reserves ⓘ	78.89	-34.48	-40.92	-49.71	-60.67	-71.11	-75.97	-81.98	-82.64	-83.32
Debt +	15.28	14.76	9.85	9.13	10.33	11.33	12.02	13.12	14	14.52
Long Term Debt	6.34	5.19	3.84	4.10	4.28	4.54	4.77	4.95	5.08	6.10
Short Term Debt	8.94	9.57	6	5.04	6.05	6.79	7.25	8.17	8.92	8.42
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.84	0.54	0.55	0.29	0.38	0.24	0.20	0.23	0.20	1.59
Others Liabilities ⓘ	122.30	31.58	31.41	31.18	31.06	30.76	25.20	25.33	25.11	25.63
Total Liabilities ⓘ	293.09	88.18	76.66	66.66	56.86	46.99	37.22	32.48	32.44	34.20
Fixed Assets
Net Fixed Assets ⓘ +	140.95	61.16	50.97	41.10	31.20	21.32	11.40	6.45	6.36	7.96
Gross Block	206.42	107.86	107.55	107.58	107.58	107.61	107.61	107.61	107.61	109.31
Accumulated Depreciation	65.47	46.69	56.58	66.48	76.38	86.28	96.21	101.16	101.25	101.34
CWIP ⓘ	0.29	2.04	1.87	1.87	1.87	1.87	1.87	1.87	1.87	1.87
Investments ⓘ	92.20	0	0	0	0	0.01	0.11	0.11	0.10	0.10
Inventories	0.07	0.07	0.04	0.03	0.04	0.02	0.09	0.03	0.03	0.03
Trade Receivables	1.63	0.01	0	0	0	0	0	0	0	0
Cash Equivalents	0.03	0.05	0.10	0.10	0.04	0.01	0.02	0	0.01	0.28
Others Assets ⓘ	57.92	24.85	23.68	23.56	23.71	23.76	23.74	24.02	24.08	23.96
Total Assets ⓘ	293.09	88.18	76.66	66.66	56.86	46.99	37.22	32.48	32.44	34.20

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.02	0.02	-0.63	-1.74	0.14	0.01	0.10	0	0	1.20
PBT ⓘ	-21.54	-19.86	-6.44	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66	-0.68
Adjustment ⓘ	20.58	19.24	5.06	8.20	10.10	10	9.98	4.96	0.05	0.16
Changes in Working Capital ⓘ	0.98	0.65	0.75	-1.14	1	0.45	0.52	1.05	0.61	1.71
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.02	0	3.05	1.74	0	-0.04	-0.10	-0.01	0	-1.70
Capex	0	0	3.37	1.74	0	-0.03	0	-0	0	-1.70
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.02	0	-0.32	0	0	-0.01	-0.10	-0.01	0	0
Cash Flow From Financing Activity ⓘ +	-0	-0	-2.37	0	-0.20	0	0	0	0	0.78
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0	-0	-0.75	0	0	0	0	0	0	-0.24
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	-1.62	0	-0.20	0	0	0	0	1.02
Net Cash Flow ⓘ	-0	0.02	0.05	-0	-0.06	-0.02	0	-0.01	0	0.28

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-12.94	-20.27	-16.91	-28.87	-53.27	-105.59	N/A	N/A	N/A	N/A
ROCE (%)	-11.85	-17.1	-9.06	-21.35	-34.91	-49.07	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0	0	0	0	0	0	0	0	0.01	0.01
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	0	1,060.50	0	0	0	0	0	0	0	0
Inventory Days	132.30	85	165.90	187.40	3,548.60	63.40	242.40	425.40	52.60	47.50
Payable Days	0	0	4,078.60	4,527.50	8,270.20	1,857.70	-1,746.90	1,187.70	0	0

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Transgene Biotek Ltd FAQs

The current trading price of Transgene Biotek on 04-Jun-2026 16:59 is ₹3.13.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Transgene Biotek stood at ₹23.72 Cr

The latest P/E ratio of Transgene Biotek as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Transgene Biotek as of 03-Jun-2026 is -2.58.

The 52-week high of Transgene Biotek is ₹5.26 and the 52-week low is ₹1.83.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Transgene Biotek is ₹0.21 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transgene Biotek Ltd is a below average quality company.

The key valuation ratios of Transgene Biotek Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transgene Biotek Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Transgene Biotek Ltd

Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.

In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards. Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology. Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.

Product range of the company includes:

The company is engaged in manufacturing drugs for:

New Drug Delivery System (NDDS)

Oral Delivery of Insulin
Oral Delivery Hepatitis B Vaccine
Pegylation of Protein Drugs for Sustained Release

Biogeneries

Tacrolimus
Pegylated EPO

Human Vaccines

Meningococcal Meningitis
Universal Meningococcal Meningitis
Haemophilus Influenza B-Hib
DTP+Hib+Hep B Combination
Hepatitis A+B Combination

Cancer Drugs/Oncology

Multiple Myeloma
Barrett's Esophageal Cancer
Colon Cancer
Breast Cancer

Transgene Biotek Ltd (526139)

Transgene Biotek Ltd (526139)

Transgene Biotek stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Transgene Biotek - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Transgene Biotek Ltd FAQs

About Transgene Biotek Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Transgene Biotek Ltd (526139)

Transgene Biotek Ltd (526139)

Transgene Biotek stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Transgene Biotek - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Transgene Biotek Ltd FAQs

What is the share price of Transgene Biotek?

What is the market cap of Transgene Biotek?

What is the P/E ratio of Transgene Biotek?

What is the P/B ratio of Transgene Biotek?

What is the 52-week high and low of Transgene Biotek?

What is the TTM revenue of Transgene Biotek?

Is Transgene Biotek Ltd a good quality company?

Is Transgene Biotek Ltd undervalued or overvalued?

Is Transgene Biotek Ltd a good buy now?

About Transgene Biotek Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.